Vericel
This content is intended for Health Care Professionals in the United States.
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. Vericel markets MACI® (autologous cultured chondrocytes on porcine collagen membrane) for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients. MACI is the first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee.
For more information, please visit MACI.com.
Vericel
Cartilage Damage With Concomitant TTO + MPFL - My Surgical Approach
- 957 views
- March 29, 2023
- 3
Vericel
Patella MACI and Tibial Tubercle Osteotomy using the MD3T™ System
- 2,089 views
- January 11, 2023
- 14
Vericel
Planning Beyond Chondroplasty for Knee Cartilage Damage
- 109 views
- February 17, 2022
Vericel
MACI in the Presence of Bone Involvement
- 197 views
- February 17, 2022
- 1
Vericel
Patient Counseling on MACI or Other Cartilage Repair Options: My Approach
- 107 views
- February 17, 2022
Vericel
Addressing the Knee as an Organ when Considering Cartilage Repair Options
- 501 views
- February 9, 2022
- 4
Vericel
MACI®: Arthrotomy Approach for Optimal Exposure
- 2,761 views
- November 8, 2021
- 7
Vericel
Surgical approach for the repair of an LFC and Trochlea defect
- 423 views
- February 5, 2019
- 2
Vericel
Tibial Tubercle Osteotomy Surgical Approach
- 902 views
- November 2, 2018
- 1
Vericel
Surgical Approach & Knee Arthrotomy - Lateral Femoral Condyle Defect
- 655 views
- April 13, 2018
Vericel
(REMOVED) MACI Surgical Technique: Surgical Approach featuring Dr. Leela Biant
- 167 views
- April 13, 2018
INDICATION
MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.
Limitations of Use
- Effectiveness of MACI in joints other than the knee has not been established.
- Safety and effectiveness of MACI in patients over the age of 55 years have not been established.
IMPORTANT SAFETY INFORMATION
Contraindications: MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, products of porcine or bovine origin; in patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders; in patients who have undergone prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant; or in patients unable to cooperate with a physician-prescribed post-surgical rehabilitation program.
Warnings and Precautions:
- Malignancy: The risk of MACI in patients with malignancy in the area of cartilage biopsy or implant is unknown. Expansion of malignant or dysplastic cells present in biopsy tissue during manufacture and subsequent implantation may be
- Transmissible infectious diseases: Because patients undergoing procedures associated with MACI are not routinely tested for transmissible infectious diseases, cartilage biopsy and MACI implant may carry risk of transmitting infectious diseases.
- Presurgical Comorbidities: Local inflammation or active infection in the bone, joint, and surrounding soft tissue, meniscal pathology, cruciate ligament instability, and misalignment should be assessed and treated prior to or concurrent with MACI
- Product Sterility: Final sterility test results are not available at the time of shipping.
Adverse Reactions: The most frequently occurring adverse reactions reported for MACI (≥5%) were arthralgia, tendonitis, back pain, joint swelling, and joint effusion. Serious adverse reactions reported for MACI were arthralgia, cartilage injury, meniscus injury, treatment failure, and osteoarthritis.
Specific Populations:
- Use of MACI in pediatric patients (younger than 18 years of age) or in patients over 65 years of age has not been established.
- The MACI implant is not recommended during pregnancy. For implantations post-pregnancy, the safety of breastfeeding to an infant has not been determined.
To report negative side effects, contact Vericel Corporation at 1-800-453-6948 or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.
For more information or to view Full Prescribing Information, please go to MACI.com.